CEACAM5 and cancer: Only 48 patients with curative resections (28 men [58.3%] and 20 women [41.7%]; median age, 60 [IQR, 34-85] years; 31 [64.6%] with stage II-III and 17 [35.4%] with stage IV cancer) satisfied the inclusion criteria for this study and underwent surveillance by ctDNA assay, imaging, and measurement of CEA levels from September 1, 2019, to November 30, 2021 (eFigure 1 in the Supplement).